| Abstract |
Abstract Objective To study the ziprasidone combined mood stabilizer treatment of bipolar disorder typeⅠacute manic or mixed episode of clinical efficacy and safety. Methods In November 2017 to June 2018, 154 cases hospitalized during the period of bipolar disorder typeⅠacute manic or mixed episode hospitalized patients as the research object, randomly divided into experimental group and control group, experimental group give ziprasidone combined carbonic acid lithium or valproate treatment, control group given single carbonic acid lithium or valproate treatment.The scores and clinical efficacy of youngs mania scale (YMRS) before treatment and 2, 4 and 8 weeks after treatment were compared between the two groups to observe the occurrence of adverse reactions. Results The group×time interaction of YMRS score was not statistically significant (F=0.947,P< 0.392).After treatment for 2 weeks, 4 weeks and 8 weeks, the score reduction rate of YMRS in the experimental group was higher than that in the control group (F=16.209, P=0.027).With the increase of treatment time in the experimental group, the score reduction rate of YMRS gradually increased (F=245.385, P<0.001).The difference in effective rate between the two groups was statistically significant (91.67% vs 91.38%, 2=1.62, P<0.05).The difference of recovery rate between the two groups was statistically significant (81.25% vs 70.69%, 2=2.30, P< 0.05).Although the experimental group and the control group did not have serious drug side effects, there were differences in drug side effects between the two groups (2=4.839, P<0.05), and the incidence of side effects in the experimental group was lower than that in the control group. Conclusion Compared with the single use of mood stabilizers, ziprasidone combined carbonic acid lithium or valproate in the treatment of bipolar disorder typeⅠacute manic or mixed episode of clinical curative effect, and lower the incidence of adverse reactions.
|